OPKO Health (NASDAQ:OPK) Receives “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of OPKO Health (NASDAQ:OPK) in a research report sent to investors on Wednesday morning,Benzinga reports. The brokerage currently has a $3.00 target price on the biotechnology company’s stock. HC Wainwright also issued estimates for OPKO Health’s Q2 2025 earnings at ($0.07) EPS and FY2025 earnings at ($0.30) EPS.

OPK has been the subject of a number of other research reports. StockNews.com upgraded OPKO Health from a “sell” rating to a “hold” rating in a report on Monday, March 3rd. Barrington Research reiterated an “outperform” rating and issued a $2.25 price target on shares of OPKO Health in a report on Wednesday, March 12th.

OPKO Health Trading Up 3.9 %

OPK opened at $1.86 on Wednesday. The stock has a market cap of $1.25 billion, a price-to-earnings ratio of -9.79 and a beta of 1.70. The stock’s 50 day moving average price is $1.64 and its 200-day moving average price is $1.57. OPKO Health has a one year low of $0.87 and a one year high of $2.04. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97.

OPKO Health (NASDAQ:OPK) last announced its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.09. The firm had revenue of $183.60 million during the quarter, compared to analyst estimates of $155.42 million. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. On average, equities analysts forecast that OPKO Health will post -0.25 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Phillip Md Et Al Frost bought 200,000 shares of the stock in a transaction on Monday, March 17th. The stock was bought at an average price of $1.74 per share, for a total transaction of $348,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 213,501,448 shares in the company, valued at approximately $371,492,519.52. This represents a 0.09 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders purchased a total of 964,971 shares of company stock worth $1,493,692 over the last 90 days. Company insiders own 47.26% of the company’s stock.

Institutional Trading of OPKO Health

A number of hedge funds have recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in OPKO Health by 4.5% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 186,783 shares of the biotechnology company’s stock worth $275,000 after buying an additional 8,064 shares during the period. Two Sigma Advisers LP increased its position in shares of OPKO Health by 2.3% during the fourth quarter. Two Sigma Advisers LP now owns 381,197 shares of the biotechnology company’s stock worth $560,000 after purchasing an additional 8,396 shares in the last quarter. FMR LLC increased its position in shares of OPKO Health by 103.6% during the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 11,089 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its position in shares of OPKO Health by 75.3% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 28,908 shares of the biotechnology company’s stock worth $42,000 after purchasing an additional 12,417 shares in the last quarter. Finally, Comerica Bank increased its position in shares of OPKO Health by 18.2% during the fourth quarter. Comerica Bank now owns 106,369 shares of the biotechnology company’s stock worth $156,000 after purchasing an additional 16,369 shares in the last quarter. Hedge funds and other institutional investors own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.